RxDoctor Payments Data

Brett Meador, PA

Physician Assistant · Harrisburg, PANPI 1225493562

Payments from drug & device makers

$2,327in general payments, 2019–2025

Across 98 payments — averaging $23.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$696
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$265
  • Pfizer$195
  • Sanofi$148
  • Celltrion USA Inc.$147
  • E.r. Squibb & Sons, L.L.C.$125
  • plus $751 from 13 others

What the payments were for

  • Food & beverage$2,29198%
  • Education$362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,327 in reported general payments places this provider in the 85th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$26,311
Medicare patients
172
Services billed
370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab12$72,106
XifaxanRifaximin20$54,505
CreonLipase/Protease/Amylase19$45,301
LinzessLinaclotide21$23,149
Mesalamine21$7,659
Dexlansoprazole DrDexlansoprazole18$3,740
Pantoprazole Sodium212$2,698
Sucralfate69$2,216
Famotidine114$1,895
Omeprazole183$1,797
Colestipol Hcl18$1,411
Esomeprazole Magnesium38$1,069
CholestyramineCholestyramine (With Sugar)17$999
Dicyclomine Hcl80$827
LoperamideLoperamide Hcl24$720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$696$68,45040 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$265$54,50520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Harrisburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →